NCT01723020 is a Phase 1 clinical trial of AMG 232 in Advanced Malignancy, sponsored by Kartos Therapeutics, Inc..

Who is sponsoring NCT01723020?

NCT01723020 is sponsored by Kartos Therapeutics, Inc..

What drugs are being tested in NCT01723020?

Interventions in NCT01723020: AMG 232.

What condition does NCT01723020 study?

NCT01723020 studies Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Glioblastoma, Multiple Myeloma.

Is NCT01723020 still recruiting?

NCT01723020 is currently completed. Last updated 2 September 2021.

Last reviewed 2021-09-02 · How we verify

NCT01723020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Completed Phase 1 Last updated 2 September 2021

What this trial tests

Phase 1 trial testing AMG 232 in Advanced Malignancy in 107 participants. Completed in 25 September 2017.

Timeline

27 December 2012

Primary endpoint
15 March 2017

25 September 2017

Quick facts

Lead sponsor	Kartos Therapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	107
Start date	27 December 2012
Primary completion	15 March 2017
Estimated completion	25 September 2017
Sites	14 locations across France, Netherlands, United States

Drugs / interventions tested

AMG 232 — full drug profile →

Conditions studied

Advanced Malignancy — all drugs for Advanced Malignancy →
Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Cancer — all drugs for Cancer →
Oncology — all drugs for Oncology →

Sponsor

Kartos Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Malignancy or Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glioma targeted therapy: insight into future of molecular approaches.
Yang K, Wu Z, Zhang H, Zhang N, et al · · 2022 · cited 518× · PMID 35135556 · DOI 10.1186/s12943-022-01513-z
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Clinical Overview of MDM2/X-Targeted Therapies.
Burgess A, Chia KM, Haupt S, Thomas D, et al · · 2016 · cited 242× · PMID 26858935 · DOI 10.3389/fonc.2016.00007
The Role of p53 Signaling in Colorectal Cancer.
Liebl MC, Hofmann TG. · · 2021 · cited 231× · PMID 33924934 · DOI 10.3390/cancers13092125
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, et al · · 2024 · cited 195× · PMID 39048965 · DOI 10.1186/s12943-024-02046-3
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V, Voltan R, Gonelli A, Secchiero P, et al · · 2017 · cited 191× · PMID 28673313 · DOI 10.1186/s13045-017-0500-5
Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, et al · · 2024 · cited 147× · PMID 38473776 · DOI 10.3390/ijms25052529
Role of p53 in breast cancer progression: An insight into p53 targeted therapy.
Marvalim C, Datta A, Lee SC. · · 2023 · cited 142× · PMID 36923534 · DOI 10.7150/thno.81847

Verify or expand the search:

Other trials of AMG 232

Trials testing the same drug.

NCT02110355 — A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma · Phase 1 · completed
NCT02016729 — A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia · Phase 1 · completed

Other recruiting trials for Advanced Malignancy

Currently open trials in the same condition.

NCT07238075 — ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers · Phase 1 · recruiting

Other Kartos Therapeutics, Inc. trials

Trials by the same sponsor.

NCT06479135 — Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp · Phase 3 · recruiting
NCT05027867 — KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer · Phase 2 · terminated
NCT04835584 — KRT-232 and TKI Study in Chronic Myeloid Leukemia · Phase 1, PHASE2 · recruiting
NCT04640532 — KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF · Phase 1, PHASE2 · unknown
NCT04113616 — An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combin · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01723020 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kartos Therapeutics, Inc.
Last refreshed: 2 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01723020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing